Hisamitsu Pharmaceutical Co

4530.T

Filed as Hisamitsu Pharmaceutical Co.,Inc. (2022-07–2025-10)

Key numbers · FY ended 2025-02

Revenue¥156.0bn+10.1% YoY Operating income¥18.9bn+43.5% YoY Net income (owners)¥21.8bn+55.8% YoY Total assets¥343.1bn+4.3% YoY EPS (basic)¥295.57+62.7% YoY

Full financial history and reports →

Stock price4530 · View chart ↗

Open the price chart on TradingView.

Latest filings

Thu, Apr 30 · JST1 filing

14:075% STAKEHisamitsu Pharmaceutical Co · TAIYO KOSAN CO., INC. + 7 joint holders · 63.43% → 63.43%

Tue, Apr 28 · JST1 filing

13:17MATERIALHisamitsu Pharmaceutical Co · Change in major shareholder

Mon, Mar 2 · JST1 filing

10:435% STAKEHisamitsu Pharmaceutical Co · - + 2 joint holders · 5.64% → 1.08%−4.56pp

Fri, Feb 27 · JST2 filings

16:165% STAKEHisamitsu Pharmaceutical Co · TAIYO KOSAN CO., INC. + 7 joint holders · 63.43% → 63.43%16:145% STAKEHisamitsu Pharmaceutical Co · TAIYO KOSAN CO., INC. + 7 joint holders · 8.13% → 63.43%+55.30pp

All filings →

Major holders (5%+) · 3

Holder	Stake	Change	Filed
TAIYO KOSAN CO., INC.	32.13%	-25.84pp	2026-04-30
Nakatomi Kazuhide	31.27%	+30.85pp	2026-04-30
CREDIT INDUSTRIEL ET COMMERCIAL	9.43%	+1.72pp	2026-05-12

Each holder's own ratio from its most recent large-shareholding report.